Patents Issued in July 16, 2020
-
Publication number: 20200222522Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.Type: ApplicationFiled: September 12, 2019Publication date: July 16, 2020Inventors: Richard Malley, Yingjie Lu, Fan Zhang, Teresa J. Broering, Shite Sebastian, Velupillai Puvanesarajah, George R. Siber
-
Publication number: 20200222523Abstract: The present invention provides genetically engineered strains of the Bordetella species to include one or more mutations preventing expression of the gene encoding the Bordetella Sigma Regulator (also referred to as “bsr,” “btrS,” and “brpL”), compositions and vaccines thereof, and the use of such engineered strains in methods to protect against Bordetella spp, including but not limited to Bordetella bronchiseptica, B. pertussis, B. parapertussis, B. homelsii, or B. avium. In some aspects, the present invention provides the Bordetella bronchiseptica strain RB50?bsr, compositions and vaccines thereof, and the use of Bordetella bronchiseptica strain RB50?fer in methods to protect against Bordetella spp, including but not limited to Bordetella bronchiseptica, B. pertussis, B. parapertussis, B. homelsii, or B. avium.Type: ApplicationFiled: September 28, 2018Publication date: July 16, 2020Inventors: Eric T. Harvill, Monica Cartelle Gestal
-
Publication number: 20200222524Abstract: Provided are stable virus formulations that contain at least three amino acids, at least one protein, at least one carbohydrate, and at least one salt. In certain embodiments, amino acid combinations with either at least three, or four, or more amino acids are included. By virtue of inclusion of the amino acids, a virus in the formulations is physically and biologically stable both in liquid and dry powder state. In further embodiments, by virtue of inclusion of the amino acids, a virus in the formulations is physically and biologically stable during lyophilization process. In further embodiments, by virtue of inclusion of the amino acids, a virus in the formulations is physically and biologically stable during storage in both liquid and lyophilized states.Type: ApplicationFiled: March 24, 2020Publication date: July 16, 2020Applicant: Vaccine Stabilization InstituteInventors: Byeong Seon Chang, Jeong S. Oh
-
Publication number: 20200222525Abstract: The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies. Further provided are novel antibodies against influenza.Type: ApplicationFiled: September 12, 2019Publication date: July 16, 2020Inventor: Sabariah Schrader
-
Publication number: 20200222526Abstract: Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity.Type: ApplicationFiled: July 16, 2018Publication date: July 16, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kathryn HASHEY, Padma MALYALA, Marcelo SAMSA, Olga SLACK, Dong YU, Alan STOKES, Rashmi JALAH
-
Publication number: 20200222527Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.Type: ApplicationFiled: February 4, 2020Publication date: July 16, 2020Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Publication number: 20200222528Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.Type: ApplicationFiled: April 27, 2018Publication date: July 16, 2020Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
-
Publication number: 20200222529Abstract: A composition for treating and/or preventing Hepatitis B virus infection and Hepatitis B virus infection mediated diseases and the method thereof are provided. In some embodiments, the composition includes a polyriboinosinic acid-polyribocytidylic acid (PIC), at least one antibiotic or polyamide compound, at least one positive ion, and Hepatitis B virus surface antigen. In some embodiments, the composition includes PIC, at least one antibiotic or polyamide compound, at least one positive ion, Hepatitis B virus surface antigen and Hepatitis B virus core antigen. The present disclosure also relates to a method of treating and/or preventing Hepatitis B virus infection, particularly for treating chronic HBV infection.Type: ApplicationFiled: August 1, 2018Publication date: July 16, 2020Inventor: Yi ZHANG
-
Publication number: 20200222530Abstract: A preparation comprising peptides from natural allergens for use in the prevention of development of allergy.Type: ApplicationFiled: October 5, 2017Publication date: July 16, 2020Inventors: Thierry LEGON, Gaetan THIRION
-
Publication number: 20200222531Abstract: Provided herein are methods of populating a target tissue of interest of a subject with precipitated particles of a modified or synthesized substance of interest, in which tissue the precipitated particles remain where they are formed for a sufficient time to begin their interaction with the physiology of the recipient in the physical state and locations in which they were formed, when the unmodified/unsynthesized form of the substance does not innately have the requisite solubility properties to be delivered to such tissues within the body of a designated target tissue by precipitation. The present methods include precipitating particles of the modified or synthesized substance within the target tissue by administering a solution to the target tissue of interest of a subject.Type: ApplicationFiled: October 26, 2019Publication date: July 16, 2020Inventors: Robert E. Coifman, Catherine F. Yang
-
Publication number: 20200222532Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.Type: ApplicationFiled: December 18, 2019Publication date: July 16, 2020Inventors: Johannes DE HAARD, Samson FUNG, Nicolas LEUPIN, Adrian OCHSENBEIN, Carsten RIETHER, Luc VAN ROMPAEY
-
Publication number: 20200222533Abstract: Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.Type: ApplicationFiled: January 10, 2020Publication date: July 16, 2020Inventor: Randal Tanh Hoang Pham
-
Publication number: 20200222534Abstract: The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.Type: ApplicationFiled: December 9, 2019Publication date: July 16, 2020Inventors: Julia Schnieders, Dirk Usener, Sabrina Ruggeberg, Ahmed Youssef, Martina Kirsch, Annika Hagendorf
-
Publication number: 20200222535Abstract: The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent.Type: ApplicationFiled: January 7, 2020Publication date: July 16, 2020Inventors: Angela Blake-Haskins, Tristan Marshall, Melissa D. Perkins, Kristin O'Berry
-
Publication number: 20200222536Abstract: The present disclosure provides biophotonic compositions comprising one or more fungal-derived chromophores and methods useful in phototherapy. In particular, the biophotonic compositions and the methods of the present disclosure are useful for the treatment of rare diseases that afflict skin or soft tissues. The present disclosure also provides a photoactivatable fabric composition in combination with the biophotonic compositions.Type: ApplicationFiled: May 23, 2017Publication date: July 16, 2020Inventors: Francesco BELLINI, Nikolaos LOUPIS, Remigio PIERGALLINI, Andreas NIKOLIS, Giovanni SCAPAGNINI
-
Publication number: 20200222537Abstract: The present disclosure provides biophotonic compositions comprising one or more photosynthetic organism-derived chromophores or a non-photosynthetic prokaryote-derived chromophores and methods useful in phototherapy. In particular, the biophotonic compositions and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various other skin disorders.Type: ApplicationFiled: May 23, 2017Publication date: July 16, 2020Inventors: Nikolaos LOUPIS, Remigio PIERGALLINI
-
Publication number: 20200222538Abstract: Techniques are provided for administering combination of drug treatments to a patient. Information is analyzed pertaining to individual drug treatments from structurally or functionally defined drugs, drugs with unknown functions, and corresponding effects, wherein the information includes omic data including genes, transcripts, proteins, as well as experimental data from published documents. One or more combinations of drug treatments are identified with combined effects producing a positive result, wherein the positive result is directed to a specific aspect of patient health. The identified combination of drug treatments are administered to a patient.Type: ApplicationFiled: January 15, 2019Publication date: July 16, 2020Inventors: Marta Sanchez-Martin, Claudia S. Huettner, Jia Xu, Cheryl L. Eifert, Elinor Dehan, Shang Xue, Vanessa Michelini
-
Publication number: 20200222539Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.Type: ApplicationFiled: March 30, 2020Publication date: July 16, 2020Inventor: Herriot Tabuteau
-
Publication number: 20200222540Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.Type: ApplicationFiled: January 13, 2020Publication date: July 16, 2020Applicant: SIRNA THERAPEUTICS, INC.Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
-
Publication number: 20200222541Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.Type: ApplicationFiled: January 11, 2019Publication date: July 16, 2020Inventors: Ritesh Sanghvi, Matthew Miller, Andreas Grill, Yun Mo, Mohammad Mafruhul Bari, Matthew Ronsheim, Joseph Stainkamp
-
Publication number: 20200222542Abstract: The present invention relates to a transdermal nano-carrier and, more specifically, to a nano-carrier having a chitosan-based nano-sponge structure. According to the present invention, as a nano-carrier having enhanced transdermal delivery on the basis of a complex containing chitosan is provided, it is possible to effectively deliver drugs, cosmetic materials, etc. into the skin.Type: ApplicationFiled: June 14, 2018Publication date: July 16, 2020Inventors: WON IL CHOI, SUNG HYUN KIM, YONG CHUL SHIN, JEUNG HOON LEE, JIN HWA KIM, YOUNG SUNG YUN
-
Publication number: 20200222543Abstract: A method for delivering therapeutics includes infusing a hydrogel with cannabis; and contacting the hydrogel infused with cannabis into a human which causes the controlled timed releasing of the cannabis with hydrophobic molecules to permeate through a lipid pathway.Type: ApplicationFiled: January 24, 2020Publication date: July 16, 2020Inventor: Shabana Naheed
-
Publication number: 20200222544Abstract: Film products, especially suitable for oral delivery, which can be formed during manufacture in the form of large and/or heavy film strips or sheets and subsequently cut into uniform dosage units, each dosage unit being uniform in content and having distributed therein a linear polysaccharide, such as pullulan, a plasticizer, and an active component.Type: ApplicationFiled: March 26, 2020Publication date: July 16, 2020Inventors: Garry L. Myers, Michael Li, Beuford Arlie Bogue, Eric Dadey
-
Publication number: 20200222545Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.Type: ApplicationFiled: March 23, 2020Publication date: July 16, 2020Applicant: Genentech, Inc.Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
-
Publication number: 20200222546Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.Type: ApplicationFiled: August 19, 2019Publication date: July 16, 2020Inventor: Marek Kwiatkowski
-
Publication number: 20200222547Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.Type: ApplicationFiled: September 19, 2019Publication date: July 16, 2020Applicant: Genentech, Inc.Inventors: Sebastian STARK, Thomas KNAPPE, Harald RAU, Nicola BISEK, Burkhardt LAUFER, Samuel WEISBROD, Tobias VOIGT, Germaine FUH, Patrick KOENIG, Chingwei Vivian LEE, Daniela BUMBACA YADAV
-
Publication number: 20200222548Abstract: Provided herein are bioconjugates comprising a backbone and at least one branched or unbranched peptide having at least one collagen-binding unit covalently bonded thereto via a spacer and methods of use thereof.Type: ApplicationFiled: July 9, 2018Publication date: July 16, 2020Inventors: John Eric Paderi, Julia Chen, Sharmistha Saha
-
Publication number: 20200222549Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptide-active agent conjugates are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the kidney. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to targe regions, tissues, structures, or cells targeted by the peptide.Type: ApplicationFiled: June 14, 2018Publication date: July 16, 2020Inventors: Julia E. Novak, Natalie Winblade Narin, Dennis M. Miller
-
Publication number: 20200222550Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.Type: ApplicationFiled: January 30, 2018Publication date: July 16, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Michael Albert Winters, John E. MacNair
-
Publication number: 20200222551Abstract: Embodiments herein report compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.Type: ApplicationFiled: October 10, 2019Publication date: July 16, 2020Applicants: The Regents of the University of Colorado, a Body Corporate, Konkuk University Industry Cooperation FoundationInventors: SooHyun Kim, Charles A. Dinarello
-
Publication number: 20200222552Abstract: This disclosure is directed to antibody-drug conjugates. More specifically, this disclosure is directed to compositions comprising (i) antibody-drug conjugates comprising benzodiazepines, and (ii) a small hydrophobic molecule, methods of treatment using the compositions, and methods of formulating the compositions. Furthermore, this disclosure is directed to methods of reducing reversible self-association in antibodies and in antibody-drug conjugates.Type: ApplicationFiled: November 12, 2019Publication date: July 16, 2020Inventor: Elizabeth Bartlett
-
Publication number: 20200222553Abstract: The present invention provides improved processes for the preparation of drug-linkers with a ?-glucuronide cleavable unit, as well as intermediates thereof.Type: ApplicationFiled: March 23, 2018Publication date: July 16, 2020Applicant: SEATTLE GENETICS, INC.Inventors: Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
-
Publication number: 20200222554Abstract: Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, L, L1, L2, L3, L4, L5, L6, M, m, and p are as defined herein. Methods associated with preparation and use of such compounds is also provided.Type: ApplicationFiled: October 5, 2018Publication date: July 16, 2020Inventors: Tracy MATRAY, Hesham SHERIF
-
Publication number: 20200222555Abstract: Provided herein are methods of treating cancer by performing first and second administrations of induced tumor homing therapeutic cells to a subject. In some embodiments, the first administration comprises administering the induced tumor homing therapeutic cells to a surgical site and the second administration comprises administering the induced tumor homing therapeutic cells to a subject parentally. Also described herein are pharmaceutical compositions comprising induced tumor homing therapeutic cells.Type: ApplicationFiled: January 15, 2020Publication date: July 16, 2020Inventor: Susan B. NICHOLS
-
Publication number: 20200222556Abstract: The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.Type: ApplicationFiled: December 20, 2019Publication date: July 16, 2020Applicant: Codiak BioSciences, Inc.Inventors: Kevin P. DOOLEY, Rane A. HARRISON, Russell E. MCCONNELL, Ke XU, Damian J. HOUDE, Nikki ROSS, Sonya HAUPT, John D. KULMAN, Douglas E. WILLIAMS
-
Publication number: 20200222557Abstract: Disclosed herein, inter alia, are compositions and methods of modulating macrophage activity. Provided is a method of treating a disease (e.g., a macrophage-associated disease, autoimmune disease, inflammatory disease, or a cancer of an organ in the intraperitoneal cavity), the method including intraperitoneally administering to a subject in need thereof a therapeutically effective amount of a nanoparticle composition or pharmaceutical composition. Provided is a silica nanoparticle non-covalently bound to a plurality of nucleic acids, wherein the silica nanoparticle has a net positive charge in the absence of the plurality of nucleic acids. Provided is a pharmaceutical composition including a nanoparticle composition as described herein, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: June 29, 2018Publication date: July 16, 2020Inventors: Jacob Berlin, Tom Haber, Yvonne Cornejo
-
Publication number: 20200222558Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof:Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.Type: ApplicationFiled: November 22, 2019Publication date: July 16, 2020Inventors: Frank DeRosa, Michael Heartlein
-
Publication number: 20200222559Abstract: The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.Type: ApplicationFiled: May 30, 2019Publication date: July 16, 2020Inventors: Satheesh Elangovan, Sheetal Reginald R. D'mello, Anh-Vu T. Do, Liu Hong, Behnoush Khorsand-Sourkohi, Aliasger K. Salem, Michael Kormann
-
Publication number: 20200222560Abstract: Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T1 contrast enhancement (T1˜0.900 ms) in the rim over at least 3 weeks with clinically observable resolution.Type: ApplicationFiled: May 24, 2018Publication date: July 16, 2020Inventors: Thomas Andresen, Rasmus Irming Jølck, Linda Maria Bruun
-
Publication number: 20200222561Abstract: A method for conducting an ultrasound session using an ultrasound probe system includes the steps of providing an ultrasound gel for use in combination with the ultrasound probe system, the ultrasound gel defining a composition including 1-10% by weight of Carbopol; 0.001-0.02% by weight of fungistat; 0.001-0.02% by weight of NaOH; 0.001-0.02% by weight of chlorhexidine; 1-5% by weight of glycerin up; 90-95% by weight of purified water; 0.001-0.02% by weight of curacao; 0.1-0.8% by weight of aloe vera leaf juice; 0.01-0.03% by weight of citric acid; 0.001-0.02% by weight of EDTA disodium; 0.001-0.02% by weight of phenoxyethanol; 0.001-0.02% by weight of ethylhexylglycerin; and 0.001-0.02% by weight of methylisothiazolinone; and selectively applying the ultrasound gel on an ultrasound site and operating the ultrasound probe system thereon.Type: ApplicationFiled: March 30, 2020Publication date: July 16, 2020Applicant: MYT Enterprises LLCInventor: Menachem Treff
-
Publication number: 20200222562Abstract: Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5.Type: ApplicationFiled: August 26, 2019Publication date: July 16, 2020Applicant: Lantheus Medical Imaging, Inc.Inventors: James F. Castner, Dianne D. Zdankiewicz, James E. Anderson
-
Publication number: 20200222563Abstract: Fluoridated organofluoroborates comprising at least one 18F atom and precursors thereto, for use in PET scanning.Type: ApplicationFiled: January 17, 2020Publication date: July 16, 2020Inventors: DAVID PERRIN, ZHIBO LIU
-
Publication number: 20200222564Abstract: Disclosed is a composite amphiphilic peptide nanomicelle, the preparation method and application, as to a novel integrin ?v?3-targeted amphiphilic peptide nanomicelles, the applications in fluorescence imaging, photodynamic therapy, sonodynamic therapy and combined treatments. Based on the prominent properties of integrin ?v?3-targeted amphiphilic peptide nanomicelles such as great biocompability, fluorescence imaging of encapsulated materials, photodynamic therapy and photothermal therapy, it is promising to be widely used in the field of labeling and tracing in vivo, biomedical imaging, early detection and treatment for tumor. It has good economic and social benefits in terms of life health and personalized medicine.Type: ApplicationFiled: April 24, 2019Publication date: July 16, 2020Applicant: Tianjin UniversityInventor: Zhe LIU
-
Publication number: 20200222565Abstract: A sanitation assembly (1) comprising a first chamber (2) with a first volume (2a) for receiving a first fluid, and a second chamber (3) with a second volume (3a) for receiving a second fluid, wherein the first volume (2a) communicates with an outlet (6) of the assembly (1) via a first valve mechanism (4) configured to allow discharge of the fluid from the first volume (2a) to the outlet (6) at a predefined first opening pressure, wherein the second volume (3a) communicates with the outlet (6) of the assembly (1) via a second valve mechanism (5) configured to allow discharge of the fluid from the second volume (3a) to the outlet (6) at a predefined second opening pressure, and wherein the predefined second opening pressure of the second valve mechanism (5) is higher than the predefined first opening pressure of the first valve mechanism (4).Type: ApplicationFiled: September 24, 2018Publication date: July 16, 2020Applicant: Merck Patent GmbHInventor: Fabrice COMINI
-
Publication number: 20200222566Abstract: Various embodiments of the present invention relate to, among other things, a nano carrier platform for generating enhanced engineered water nanostructures (iEWNS) encapsulating and delivering reactive oxygen species (ROS) and, in some instances, other active ingredients, methods for inactivating at least one of viruses, bacteria, bacterial spores, and fungi on a substrate by applying iEWNS to the substrate.Type: ApplicationFiled: August 17, 2018Publication date: July 16, 2020Inventors: Philip Demokritou, Nachiket Dattatray Vaze, Georgios Pyrgiotakis, Mary Eleftheriadou
-
Publication number: 20200222567Abstract: A scalable, portable and modular chlorine dioxide fumigant decontamination system having an activating area and a neutralizing area which may be housed separately or as a single operationally connected unit, and which may be configured as a closed loop system connected to a decontamination chamber for decontamination of articles, or as an open loop system for decontamination of interiors and large confined spaces, and employing a specialized activating cup that is permeable to air yet substantially impermeable to water and chlorine dioxide reaction by-products such that directing air through the activation cup releases nearly pure chlorine dioxide fumigant. Methods and articles relating to the system are also described.Type: ApplicationFiled: March 22, 2020Publication date: July 16, 2020Inventors: Lawrence F. Bender, James F. Knoer
-
Publication number: 20200222568Abstract: This disclosure relates to a device for disinfecting equipment, such as medical devices, surgical equipment, and/or CPAP components (or, CPAP equipment), including the various parts of a CPAP system, such as hoses, masks, pillows, couplings, humidifiers, etc., that require frequent cleaning and disinfecting. An example device includes a chamber, an ultraviolet (UV) light configured to emit UV light within the chamber, an ozone generator configured to generate ozone within the chamber, and a control unit configured to activate the UV light and the ozone generator simultaneously for a first period of time. A method is also disclosed.Type: ApplicationFiled: March 30, 2020Publication date: July 16, 2020Inventor: Albert A. Lucio
-
Publication number: 20200222569Abstract: Methods and test kits are provided for assessing effectiveness of an individual's hand cleansing technique. One method includes donning a glove on one hand and another glove on the other, which then are engaged for a desired period of time. The gloves are removed and the hands cleansed. Thereafter, a third glove is donned on one hand and a fourth glove on the other, which again are engaged. Alternatively or additionally, at least one fingertip on one hand optionally can be swabbed with a swab device to collect a sample from the fingertip, then the hands cleansed. At least one cleansed fingertip can be swabbed with a swab device to collect a sample. The gloves and/or test swab(s) can be sent to a lab and tested for a microbe presence to assesses effectiveness of an individual's hand cleansing technique. Kits can be provided to aid in carrying out said methods.Type: ApplicationFiled: January 16, 2019Publication date: July 16, 2020Inventors: Bradley J. Bushman, Patrick Bird, Dane Brooks
-
Publication number: 20200222570Abstract: A sanitation management system maintains records of exemplary locations on an item to be sanitized and indicates those locations to a person or system charged with applying a pathogen surrogate prior to a sanitation process. The sanitation management system maintains records of where the pathogen surrogate was applied prior to the sanitation process. Following the sanitation process, the sanitation management system indicates to an inspector, or an inspection system, locations of where the pathogen surrogate was applied for the purpose of facilitating testing of the sanitation process by checking for the presence of the pathogen surrogate at some or all of those locations. This can ensure that the inspection process is relevant to the sanitation process and less likely to generate false negatives where the inspection finds a lack of the pathogen surrogate not due to cleaning, but due to lack of application of the pathogen surrogate.Type: ApplicationFiled: January 13, 2020Publication date: July 16, 2020Inventors: Antonios Zografos, Laurie M. Clotilde, Peter Mattei
-
Publication number: 20200222571Abstract: An aromatherapy device includes an aroma diffuser using a hollow heating element to heat thermal conduction device that is used to heat a disposable multilayer breathing film-based aroma capsule or aromatic substances in a detachable aromatic substance container for producing fragrance. The hollow heating element produces heat energy to the thermal conduction device without causing concentration of heat source, so that the thermal conduction device can evenly heat the disposable multilayer breathing film-based aroma capsule or the aromatic substances in the detachable aromatic substance container for producing fragrance in the space, enabling the aromatic substances to be completely vaporized without leaving a residue.Type: ApplicationFiled: March 24, 2020Publication date: July 16, 2020Inventor: Ming Jen HSIAO